AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life ...

Apellis' C3 inhibitor Empaveli (pegcetacoplan) is also approved for PNH, and is given by subcutaneous infusion, but remains a relatively minor product with sales of less than $25 million in the ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

Gaining approval for subcutaneous Keytruda would expand access ... In its IV form, Keytruda is administered at infusion centers, with the procedure taking approximately 30 minutes, every three ...

If approved, this option would allow patients to begin treatment with under-the-skin or subcutaneous (SC) injections instead ...

The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ®, together with ...